The company launched ONAPGO™, a new treatment for Parkinson's disease, in April 2025 and saw significant growth in Qelbree prescriptions, which rose by 22%. Supernus reiterated its full year ...

Pipeline assets like Onapgo and potential acquisitions could bolster growth, but uncertainties remain, especially with SPN-820's recent trial failure. I'm downgrading SUPN stock from "Buy" to ...

First quarter adjusted operating earnings (non-GAAP) (1) increased 16% to $25.9 million. ONAPGO™ (apomorphine hydrochloride) launched in the U.S. in April 2025. The Company reiterates full year ...

Discussion on ONAPGO's launch highlighted initial positive reception and the expectation of moderate sales contributions in 2025. Analysts expressed cautious optimism, focusing on growth ...

“In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson’s disease who are experiencing motor ...

First quarter adjusted operating earnings (non-GAAP) (1) increased 16% to $25.9 million. ONAPGO™ (apomorphine hydrochloride) launched in the U.S. in April 2025. The Company reiterates full year 2025 ...